BioCentury | Mar 2, 2021
Product Development

March 2 Quick Takes: Merck to help manufacture J&J COVID vaccine; plus EMA, Neurocrine, and FDA reviews for Merck, Avadel and argenx

...COVID vaccineEMA’s CHMP will meet on March 11 to complete its assessment of J&J’s COVID-19 vaccine. Neurocrine’s...
...of schizophrenia in the Phase II INTERACT study, but met the secondary cognitive assessment endpoint. Neurocrine...
...second half.TARGETSFCRN (FCGRT) –Neonatal Fc receptorP2X3 – Purinergic receptor P2X ligand-gated ion channel 3 BC Staff argenx S.E. Neurocrine Biosciences Inc. Merck...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...other existing investors participated in the round.Another deal termination for VoyagerVoyager Therapeutics Inc. (NASDAQ:VYGR) and Neurocrine Biosciences Inc....
...their gene therapy partnership following a December letter from FDA placing a clinical hold on Neurocrine’s...
...eligible for research, development and regulatory milestones, plus royalties. BC Staff Tepmetko (tepotinib, MSC2156119J) Hillhouse Capital Merck KGaA Reverie Labs Inc. Neurocrine Biosciences Inc. InnoCare...
BioCentury | Oct 23, 2020
Finance

Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

...third preclinical gene therapy is part of a partnership between Voyager Therapeutics Inc. (NASDAQ:VYGR) and Neurocrine Biosciences Inc....
BioCentury | Jul 22, 2020
Emerging Company Profile

Jnana goes after metabolism-mediating proteins, gains Roche as partner

...funding and royalties. The Roche deal is Jnana’s second in neurology. The biotech partnered with Neurocrine Biosciences Inc....
...Ramnik Xavier, Joanne Kotz and Joel Barrish University collaborators: Undisclosed Corporate partners: Roche (SIX:ROG; OTCQX:RHHBY), Neurocrine Biosciences Inc....
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

...receives $120M up front for seven neurology therapies Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc....
...canakinumab (ACZ885) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) avalglucosidase alfa, NeoGAA, Neo-GAA (GZ402666) Jazz Pharmaceuticals plc PharmaMar S.A. Takeda Pharmaceutical Co. Ltd. Neurocrine Biosciences Inc. Illumina...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

...ROS1, TrkA, TrkB, TrkC and ALK. FDA approves fibroid-associated menstruation therapy AbbVie Inc. (NYSE:ABBV) and Neurocrine Biosciences Inc....
...Staff Writer, and Robin Sawka, BioCentury Staff Piqray, alpelisib (BYL719) Rozlytrek, entrectinib (RG6268, rxdx-101) Johnson & Johnson Novartis AG AbbVie Inc. Neurocrine Biosciences Inc. Shionogi...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...in milestone payments. Approval for Neurocrine’s Parkinson’s therapy FDA approved once-daily oral Ongentys opicapone from Neurocrine Biosciences Inc....
BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

...years,” he said. Tildacerfont does have at least one direct competitor from the same class. Neurocrine Biosciences Inc....
...began a Phase II proof-of-concept study of the therapy to treat pediatric classic CAH. Although Neurocrine...
...it. “Their results have not been presented anywhere,” he said. In a statement to BioCentury, Neurocrine...
BioCentury | Dec 3, 2019
Company News

Xenon licenses sodium channel inhibitors to Neurocrine to fund more advanced epilepsy programs

...Xenon has exclusively licensed its sodium channel inhibitors for epilepsy to Neurocrine to focus on advancing...
...advancing its potassium channel modulators through the clinic. The deal adds a new indication to Neurocrine's...
...Phase III trial of XEN496 in children with epilepsy associated with KCNQ2-associated epilepsy with encephalopathy. Neurocrine Biosciences Inc....
BioCentury | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

...and that it hired Ernst & Young as an external auditor. David Boyer has joined Neurocrine Biosciences Inc....
...“4BIO Hopes to Mix and Match Next-Gen Therapies with $150M Fund” ). BioCentury Staff Vertex Pharmaceuticals Inc. Nektar Therapeutics Neurocrine Biosciences Inc. Neovacs...
Items per page:
1 - 10 of 719
BioCentury | Mar 2, 2021
Product Development

March 2 Quick Takes: Merck to help manufacture J&J COVID vaccine; plus EMA, Neurocrine, and FDA reviews for Merck, Avadel and argenx

...COVID vaccineEMA’s CHMP will meet on March 11 to complete its assessment of J&J’s COVID-19 vaccine. Neurocrine’s...
...of schizophrenia in the Phase II INTERACT study, but met the secondary cognitive assessment endpoint. Neurocrine...
...second half.TARGETSFCRN (FCGRT) –Neonatal Fc receptorP2X3 – Purinergic receptor P2X ligand-gated ion channel 3 BC Staff argenx S.E. Neurocrine Biosciences Inc. Merck...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...other existing investors participated in the round.Another deal termination for VoyagerVoyager Therapeutics Inc. (NASDAQ:VYGR) and Neurocrine Biosciences Inc....
...their gene therapy partnership following a December letter from FDA placing a clinical hold on Neurocrine’s...
...eligible for research, development and regulatory milestones, plus royalties. BC Staff Tepmetko (tepotinib, MSC2156119J) Hillhouse Capital Merck KGaA Reverie Labs Inc. Neurocrine Biosciences Inc. InnoCare...
BioCentury | Oct 23, 2020
Finance

Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

...third preclinical gene therapy is part of a partnership between Voyager Therapeutics Inc. (NASDAQ:VYGR) and Neurocrine Biosciences Inc....
BioCentury | Jul 22, 2020
Emerging Company Profile

Jnana goes after metabolism-mediating proteins, gains Roche as partner

...funding and royalties. The Roche deal is Jnana’s second in neurology. The biotech partnered with Neurocrine Biosciences Inc....
...Ramnik Xavier, Joanne Kotz and Joel Barrish University collaborators: Undisclosed Corporate partners: Roche (SIX:ROG; OTCQX:RHHBY), Neurocrine Biosciences Inc....
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

...receives $120M up front for seven neurology therapies Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc....
...canakinumab (ACZ885) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) avalglucosidase alfa, NeoGAA, Neo-GAA (GZ402666) Jazz Pharmaceuticals plc PharmaMar S.A. Takeda Pharmaceutical Co. Ltd. Neurocrine Biosciences Inc. Illumina...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

...ROS1, TrkA, TrkB, TrkC and ALK. FDA approves fibroid-associated menstruation therapy AbbVie Inc. (NYSE:ABBV) and Neurocrine Biosciences Inc....
...Staff Writer, and Robin Sawka, BioCentury Staff Piqray, alpelisib (BYL719) Rozlytrek, entrectinib (RG6268, rxdx-101) Johnson & Johnson Novartis AG AbbVie Inc. Neurocrine Biosciences Inc. Shionogi...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...in milestone payments. Approval for Neurocrine’s Parkinson’s therapy FDA approved once-daily oral Ongentys opicapone from Neurocrine Biosciences Inc....
BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

...years,” he said. Tildacerfont does have at least one direct competitor from the same class. Neurocrine Biosciences Inc....
...began a Phase II proof-of-concept study of the therapy to treat pediatric classic CAH. Although Neurocrine...
...it. “Their results have not been presented anywhere,” he said. In a statement to BioCentury, Neurocrine...
BioCentury | Dec 3, 2019
Company News

Xenon licenses sodium channel inhibitors to Neurocrine to fund more advanced epilepsy programs

...Xenon has exclusively licensed its sodium channel inhibitors for epilepsy to Neurocrine to focus on advancing...
...advancing its potassium channel modulators through the clinic. The deal adds a new indication to Neurocrine's...
...Phase III trial of XEN496 in children with epilepsy associated with KCNQ2-associated epilepsy with encephalopathy. Neurocrine Biosciences Inc....
BioCentury | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

...and that it hired Ernst & Young as an external auditor. David Boyer has joined Neurocrine Biosciences Inc....
...“4BIO Hopes to Mix and Match Next-Gen Therapies with $150M Fund” ). BioCentury Staff Vertex Pharmaceuticals Inc. Nektar Therapeutics Neurocrine Biosciences Inc. Neovacs...
Items per page:
1 - 10 of 719